Genetic analysis company IntegenX has raised $15.6m from a consortium including In-Q-Tel, the quasi-corporate venturing unit investing on behalf of the US intelligence agencies.
IntegenX, formerly known as Microchip Biotechnologies, has also bought biotech peer GenVault.
Venture capital (VC) firms Domain Associates and RONAholdings joined In-Q-Tel in the C round. As Microchip, IntegenX previously raised $18.1m in its B round in November 2009 from Domain, Korea-based Samsung’s corporate venturing unit, debt provider Western Technology Investment, Rona and In-Q-Tel.
In-Q-Tel and Rona had previously invested $4.5m in the company’s A round in August 2006.
The acquisition of GenVault merges two of Domain’s portfolio companies. Domain had been part of a consortium investing $13m in GenVault’s series C round in June 2008, alongside VC peers Montagu Newhall Associates (now called Greenspring Associates), QuestMark Partners and Cross Creek Capital. A year earlier, GenVault raised $18m while its series A round closed at $10m in March 2003.
GenVault’s investors will take shares in IntegenX.